Jonathan Eitan Solomon - 29 Oct 2023 Form 4 Insider Report for BiomX Inc. (PHGE)

Role
Chief Executive Officer, Director
Signature
/s/ Jonathan Eitan Solomon
Issuer symbol
PHGE
Transactions as of
29 Oct 2023
Net transactions value
$0
Form type
4
Filing time
31 Oct 2023, 17:09:50 UTC
Previous filing
03 Mar 2023
Next filing
13 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer $0 -182,133 -100% $0.000000* 0 29 Oct 2023 Common Stock 0 $1.69 Direct F1
transaction PHGE Common Stock Options - Right to Buy Award $0 +182,133 $0.000000* 0 29 Oct 2023 Common Stock 0 $0.2750 Direct F1
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer $0 -201,708 -100% $0.000000* 0 29 Oct 2023 Common Stock 0 $1.97 Direct F2
transaction PHGE Common Stock Options - Right to Buy Award $0 +201,708 $0.000000* 0 29 Oct 2023 Common Stock 0 $0.2750 Direct F2
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer $0 -284,701 -100% $0.000000* 0 29 Oct 2023 Common Stock 0 $2.03 Direct F3
transaction PHGE Common Stock Options - Right to Buy Award $0 +284,701 $0.000000* 0 29 Oct 2023 Common Stock 0 $0.2750 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
F2 The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
F3 The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.